WO2005044853A3 - Anti-vegf antibodies - Google Patents

Anti-vegf antibodies Download PDF

Info

Publication number
WO2005044853A3
WO2005044853A3 PCT/US2004/029332 US2004029332W WO2005044853A3 WO 2005044853 A3 WO2005044853 A3 WO 2005044853A3 US 2004029332 W US2004029332 W US 2004029332W WO 2005044853 A3 WO2005044853 A3 WO 2005044853A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf antibodies
vegf
antibodies
binding
variants
Prior art date
Application number
PCT/US2004/029332
Other languages
French (fr)
Other versions
WO2005044853A2 (en
Inventor
Germaine Fuh
Hanspeter Gerber
Wei-Ching Liang
Frederic A Fellouse
Sachdev S Sidhu
Christian Wiesmann
Original Assignee
Genentech Inc
Germaine Fuh
Hanspeter Gerber
Wei-Ching Liang
Frederic A Fellouse
Sachdev S Sidhu
Christian Wiesmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/024662 external-priority patent/WO2005012359A2/en
Application filed by Genentech Inc, Germaine Fuh, Hanspeter Gerber, Wei-Ching Liang, Frederic A Fellouse, Sachdev S Sidhu, Christian Wiesmann filed Critical Genentech Inc
Publication of WO2005044853A2 publication Critical patent/WO2005044853A2/en
Publication of WO2005044853A3 publication Critical patent/WO2005044853A3/en
Priority to US11/414,742 priority Critical patent/US7758859B2/en
Priority to US12/816,188 priority patent/US8512699B2/en
Priority to US13/929,338 priority patent/US8975381B2/en
Priority to US14/603,693 priority patent/US20150175689A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
PCT/US2004/029332 2003-08-01 2004-09-08 Anti-vegf antibodies WO2005044853A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/414,742 US7758859B2 (en) 2003-08-01 2006-04-27 Anti-VEGF antibodies
US12/816,188 US8512699B2 (en) 2003-08-01 2010-06-15 Anti-VEGF antibodies
US13/929,338 US8975381B2 (en) 2003-08-01 2013-06-27 Anti-VEGF antibodies
US14/603,693 US20150175689A1 (en) 2003-08-01 2015-01-23 Anti-vegf antibodies

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US51649503P 2003-11-01 2003-11-01
US60/516,495 2003-11-01
US57091204P 2004-05-12 2004-05-12
US60/570,912 2004-05-12
US57123904P 2004-05-13 2004-05-13
US60/571,239 2004-05-13
US57631504P 2004-06-01 2004-06-01
US60/576,315 2004-06-01
US58075704P 2004-06-18 2004-06-18
US60/580,757 2004-06-18
PCT/US2004/024662 WO2005012359A2 (en) 2003-08-01 2004-07-30 Anti-vegf antibodies
USPCT/US2004/024662 2004-07-30

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/024662 Continuation-In-Part WO2005012359A2 (en) 2003-08-01 2004-07-30 Anti-vegf antibodies
US11/342,249 Continuation-In-Part US7811785B2 (en) 2003-08-01 2006-01-27 Anti-VEGF antibodies

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2004/024662 Continuation WO2005012359A2 (en) 2003-08-01 2004-07-30 Anti-vegf antibodies
US11/342,249 Continuation-In-Part US7811785B2 (en) 2003-08-01 2006-01-27 Anti-VEGF antibodies
US11/414,742 Continuation US7758859B2 (en) 2003-08-01 2006-04-27 Anti-VEGF antibodies

Publications (2)

Publication Number Publication Date
WO2005044853A2 WO2005044853A2 (en) 2005-05-19
WO2005044853A3 true WO2005044853A3 (en) 2006-01-05

Family

ID=34577974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/029332 WO2005044853A2 (en) 2003-08-01 2004-09-08 Anti-vegf antibodies

Country Status (1)

Country Link
WO (1) WO2005044853A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8674083B2 (en) 1999-01-15 2014-03-18 Genentech, Inc. Polypeptide variants with altered effector function
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
JP7227151B2 (en) 2017-03-22 2023-02-21 ジェネンテック， インコーポレイテッド Antibody Compositions Optimized for Treatment of Eye Disorders
US11993642B2 (en) 2009-04-07 2024-05-28 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US11999801B2 (en) 2014-12-03 2024-06-04 Hoffman-La Roche Inc. Multispecific antibodies

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP2322554A1 (en) * 2004-06-30 2011-05-18 Domantis Limited Composition comprising an anti-TNF-alpha domain antibody for the treatment of rheumatoid arthritis
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
AU2005299701B2 (en) 2004-10-21 2011-11-17 Genentech, Inc. Method for treating intraocular neovascular diseases
JP5350793B2 (en) 2005-08-31 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション Modified anti-IL-23 antibody
HUE025989T2 (en) 2006-03-21 2016-05-30 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
JP2009531463A (en) * 2006-03-29 2009-09-03 ジェネンテック・インコーポレーテッド Tumor diagnosis and treatment
CL2007001623A1 (en) 2006-06-06 2008-01-18 Genentech Inc Anti-dll4 antibody; polynucleotide that encodes it; vector and host cell comprising said polynucleotide; method for making the antibody and immunojugate; method of detection of dll4 and diagnostic method of a disorder associated with dll4; composition comprising the antibody.
CN101605814B (en) 2006-12-14 2014-02-19 默沙东公司 Engineered anti-TSLP antibody
AU2014201795B2 (en) * 2006-12-19 2016-05-19 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
KR20090114443A (en) * 2007-02-09 2009-11-03 제넨테크, 인크. Anti-Robo4 Antibodies and Uses Therefor
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
EP2059534B1 (en) 2007-02-23 2012-04-25 Schering Corporation Engineered anti-il-23p19 antibodies
CN101675076B (en) 2007-02-28 2013-09-18 默沙东公司 Engineered anti-il-23r antibodies
WO2009061807A2 (en) 2007-11-09 2009-05-14 Genentech, Inc. Activin receptor-like kinase-1 compositions and methods of use
TWI580694B (en) 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP5646457B2 (en) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
BRPI0913366A8 (en) 2008-06-03 2017-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND THEIR USES
KR20110016958A (en) 2008-06-03 2011-02-18 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
WO2009155724A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
RU2011104348A (en) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AGAINST PROSTAGLANDINE E2 AND THEIR APPLICATION
WO2010010153A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Identification of subjects being susceptible to anti-angiogenesis therapy
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2752189B1 (en) 2008-11-22 2016-10-26 F. Hoffmann-La Roche AG Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
BRPI1006270B1 (en) 2009-03-25 2022-08-16 Genentech, Inc ANTI-A5SS1 ANTIBODY, IMMUNOCONJUGATE, PHARMACEUTICAL COMPOSITION, IN VITRO OR EX VIVO METHOD TO DETECT A5SS1 PROTEIN, USE OF AN ANTIBODY AND KIT TO DETECT A5SS1 PROTEIN
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
CN102575298A (en) 2009-08-14 2012-07-11 霍夫曼-拉罗奇有限公司 Biological markers for monitoring patient response to VEGF antagonists
MX336476B (en) 2009-08-15 2016-01-20 Genentech Inc Anti-angiogenesis therapy for the treatment of previously treated breast cancer.
BR112012004823B1 (en) 2009-09-03 2021-11-30 Merck Sharp & Dohme Corp ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, USE OF AN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL COMPOSITION
EP2475996A1 (en) 2009-09-11 2012-07-18 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
SG10201408401RA (en) 2009-09-16 2015-01-29 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
CA2772670A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CA2787952C (en) 2010-02-23 2016-07-26 Genentech, Inc. Anti-angiogenesis therapy for the treatment of ovarian cancer
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
MX2013000667A (en) 2010-07-19 2013-02-27 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy.
WO2012010550A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
BR112013001847A2 (en) 2010-08-24 2016-05-31 Hoffmann La Roche bispecific antibody, method of preparation of bispecific antibody, trivalent bispecific antibody, methods and pharmaceutical composition
RU2013113225A (en) 2010-08-26 2014-10-10 Эббви Инк. IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
EA025828B1 (en) 2010-11-15 2017-02-28 Файв Прайм Терапьютикс, Инк. Fgfr1 extracellular domain combination therapies
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112013020338A2 (en) 2011-02-28 2016-10-18 Hoffmann La Roche monovalent antigen binding protein, pharmaceutical composition, use of monovalent antigen binding protein, method for treating a patient in need of therapy, method for preparing a monovalent antigen binding protein, nucleic acid, vector and cell hostess
AR085404A1 (en) 2011-02-28 2013-09-25 Hoffmann La Roche PROTEINS OF UNION TO ANTIGEN
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
PT2694072T (en) 2011-04-01 2018-02-26 Genentech Inc Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
US9932386B2 (en) 2011-04-20 2018-04-03 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
BR112014012590A8 (en) 2011-11-23 2017-12-19 Igenica Inc ANTI-CD98 ANTIBODIES AND METHODS OF THEIR USE
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
KR20140114415A (en) 2012-01-13 2014-09-26 제넨테크, 인크. Biological markers for identifying patients for treatment with vegf antagonists
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
DK2825558T3 (en) 2012-03-13 2019-07-22 Hoffmann La Roche Combination therapy for the treatment of ovarian cancer
EP2830661A4 (en) 2012-03-30 2016-05-18 Hoffmann La Roche Diagnostic methods and compositions for treatment of cancer
MY186099A (en) 2012-05-31 2021-06-22 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
BR112014028368A2 (en) 2012-06-27 2017-11-14 Hoffmann La Roche method of producing antibody fc region conjugate, antibody fc region conjugate and pharmaceutical formulation
WO2014009465A1 (en) 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
RU2015104001A (en) 2012-08-07 2016-09-27 Дженентек, Инк. COMBINED THERAPY FOR TREATMENT OF GLIOBLASTOMA
EP2906598A1 (en) 2012-10-09 2015-08-19 Igenica Biotherapeutics, Inc. Anti-c16orf54 antibodies and methods of use thereof
TW202210507A (en) 2012-11-01 2022-03-16 美商艾伯維有限公司 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
EP3252171B8 (en) 2013-05-23 2021-12-15 Five Prime Therapeutics, Inc. Methods of treating cancer
CR20160132A (en) 2013-08-12 2016-08-25 Genentech Inc COMPOSITIONS AND METHOD TO TREAT CONDITIONS ASSOCIATED WITH THE COMPLEMENT
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
MX2016003593A (en) 2013-10-11 2016-06-02 Hoffmann La Roche Multispecific domain exchanged common variable light chain antibodies.
MX365742B (en) 2013-10-11 2019-06-12 Oxford Biotherapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer.
AU2014339898B2 (en) 2013-10-25 2020-07-23 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
WO2015071348A1 (en) 2013-11-18 2015-05-21 Formycon Ag Pharmaceutical composition of an anti-vegf antibody
ES2808340T3 (en) 2014-01-24 2021-02-26 Ngm Biopharmaceuticals Inc Antibodies that bind to the beta klotho 2 domain and procedures for using them
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
BR122024001145A2 (en) 2014-03-14 2024-02-27 Novartis Ag ISOLATED ANTIBODY MOLECULE CAPABLE OF BINDING TO LAG-3, ITS PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION, NUCLEIC ACIDS, EXPRESSION VECTOR, METHOD FOR DETECTION OF LAG-3 IN A BIOLOGICAL SAMPLE, AND USE OF SAID ANTIBODY MOLECULE AND COMPOSITION
MA39776A (en) 2014-03-24 2017-02-01 Hoffmann La Roche Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
RU2016142476A (en) 2014-03-31 2018-05-07 Дженентек, Инк. COMBINED THERAPY, INCLUDING ANTI-ANGIOGENESIS AGENTS AND AGONISTS BINDING OX40
BR112016025312A2 (en) 2014-05-01 2017-10-17 Genentech Inc antibody variants, anti-d-factor antibody, pharmaceutical formulation, dispensing device, use of the formulation and a composition, composition and method of treating a disorder
EP3143044A1 (en) 2014-05-12 2017-03-22 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
DK3151921T3 (en) 2014-06-06 2019-12-02 Bristol Myers Squibb Co ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR CANCER FACTOR RECEPTORS (GITR) AND APPLICATIONS THEREOF
CN106460067A (en) 2014-07-14 2017-02-22 豪夫迈·罗氏有限公司 Diagnostic methods and compositions for treatment of glioblastoma
CA3133162C (en) 2014-08-12 2024-02-13 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
CN107106687A (en) 2014-10-03 2017-08-29 诺华股份有限公司 Combined therapy
US10894818B2 (en) 2014-10-03 2021-01-19 Massachusetts Institute Of Technology Antibodies that bind Ebola glycoprotein and uses thereof
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
CR20170143A (en) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME
JP6929771B2 (en) 2014-11-10 2021-09-01 ジェネンテック， インコーポレイテッド Anti-interleukin-33 antibody and its use
ME03806B (en) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
JP6721590B2 (en) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific antibody
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
PT3233912T (en) 2014-12-19 2021-08-09 Regenesance B V Antibodies that bind human c6 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
CN110256558B (en) 2014-12-23 2023-07-04 百时美施贵宝公司 Antibodies to TIGIT
CN107614762B (en) * 2015-02-24 2022-08-05 台湾地区“中央研究院” Single-chain variant fragment antibody library expressed by phage
SI3286315T1 (en) 2015-04-24 2021-09-30 F. Hoffmann-La Roche Ag Methods of identifying bacteria comprising binding polypeptides
ES2936317T3 (en) 2015-05-29 2023-03-16 Bristol Myers Squibb Co Antibodies against OX40 and uses thereof
US20170000885A1 (en) 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
EA201890162A1 (en) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани ANTIBODIES TO CD40 WITH ENHANCED AGONISTIC ACTIVITY
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
CA2992602A1 (en) * 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
US10421821B2 (en) 2015-10-30 2019-09-24 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
KR20180069906A (en) 2015-10-30 2018-06-25 제넨테크, 인크. Anti-Factor D antibody preparation
EA201891093A1 (en) 2015-11-03 2018-10-31 Янссен Байотек, Инк. ANTIBODIES SPECIFICALLY BINDING PD-1 AND THEIR APPLICATION
AU2016356047B2 (en) 2015-11-18 2021-10-21 Formycon Ag Pre-filled plastic syringe containing a VEGF antagonist
JP6882738B2 (en) 2015-11-18 2021-06-02 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Prefilled drug syringe containing liquid formulation of VEGF inhibitor
KR20180105123A (en) 2015-11-18 2018-09-27 에스아이오2 메디컬 프로덕츠, 인크. Pharmaceutical package for ophthalmic preparations
BR112018010172A2 (en) 2015-11-19 2018-11-21 Bristol Myers Squibb Co antibodies to glucocorticoid-induced tumor necrosis factor receptor (gitr) and their uses
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017151176A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
SG11201809793UA (en) 2016-05-09 2018-12-28 Bristol Myers Squibb Co Tl1a antibodies and uses thereof
TWI823836B (en) 2016-07-08 2023-12-01 美商建南德克公司 Use of human epididymis protein 4 (he4) for assessing responsiveness of cancer treatment
JP7050702B2 (en) 2016-07-08 2022-04-08 ジェネンテック， インコーポレイテッド Methods for diagnosing and treating cancer based on the expression status and mutation status of NRF2 and its downstream target gene
PE20190418A1 (en) 2016-07-14 2019-03-19 Bristol Myers Squibb Co ANTIBODIES AGAINST PROTEIN 3 CONTAINING THE MUCIN AND IMMUNOGLOBULIN T-LYMPHOCYTE DOMAIN (TIM3) AND THEIR USES
JP2019524820A (en) 2016-08-12 2019-09-05 ジェネンテック， インコーポレイテッド Combination therapy with MEK inhibitor, PD-1 axis inhibitor and VEGF inhibitor
CR20210094A (en) 2016-10-13 2021-03-31 Massachusetts Inst Technology Antibodies that bind zika virus envelope protein and uses thereof
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
TW201842936A (en) * 2017-03-22 2018-12-16 美商建南德克公司 Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
CA3063995A1 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
SG11201912473PA (en) 2017-06-22 2020-01-30 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Multi-cyclic aromatic compounds as factor d inhibitors
CN111886255A (en) 2018-01-12 2020-11-03 百时美施贵宝公司 anti-TIM 3 antibodies and uses thereof
CN114028568A (en) 2018-04-16 2022-02-11 上海岸阔医药科技有限公司 Method for preventing or treating side effects of tumor therapy
AU2019274657A1 (en) 2018-05-24 2020-12-10 Janssen Biotech, Inc. PSMA binding agents and uses thereof
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CN113056487A (en) 2018-09-18 2021-06-29 梅里麦克制药股份有限公司 anti-TNFR 2 antibodies and uses thereof
BR112021009111A2 (en) 2018-11-16 2021-08-24 Bristol-Myers Squibb Company Anti-nkg2a antibodies and their uses
CN113874083A (en) 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 anti-TNFR 2 antibodies and uses thereof
WO2020212947A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
EP3962947A2 (en) 2019-05-03 2022-03-09 F. Hoffmann-La Roche AG Methods of treating cancer with an anti-pd-l1 antibody
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
JP2023516459A (en) 2020-03-09 2023-04-19 ブリストル－マイヤーズ スクイブ カンパニー ANTIBODY TO CD40 WITH ENHANCED AGONISTIC ACTIVITY
MX2022011156A (en) 2020-03-13 2022-10-13 Genentech Inc Anti-interleukin-33 antibodies and uses thereof.
CA3182607A1 (en) 2020-06-30 2022-01-06 Erik Hans MANTING Use of leukemia-derived cells in ovarian cancer vaccines
WO2022157715A1 (en) 2021-01-22 2022-07-28 Dcprime B.V. Methods of tumor vaccination
EP4284838A2 (en) 2021-01-28 2023-12-06 Janssen Biotech, Inc. Psma binding proteins and uses thereof
KR20230157388A (en) 2021-03-12 2023-11-16 멘두스 비.브이. Methods of vaccination and uses of CD47 blockade

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045450A1 (en) * 1996-05-31 1997-12-04 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6416758B1 (en) * 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045450A1 (en) * 1996-05-31 1997-12-04 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6416758B1 (en) * 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BREKKEN ROLF A ET AL: "Vascular endothelial growth factor as a marker of tumor endothelium", CANCER RESEARCH, vol. 58, no. 9, 1 May 1998 (1998-05-01), pages 1952 - 1959, XP000918910, ISSN: 0008-5472 *
CHEN Y ET AL: "Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 293, no. 4, 5 November 1999 (1999-11-05), pages 865 - 881, XP004461879, ISSN: 0022-2836 *
KLOHS WAYNE D ET AL: "Antiangiogenic agents", CURRENT OPINION IN BIOTECHNOLOGY, vol. 10, no. 6, December 1999 (1999-12-01), pages 544 - 549, XP001206158, ISSN: 0958-1669 *
MORRISON KIM L ET AL: "Combinatorial alanine-scanning", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 5, no. 3, June 2001 (2001-06-01), pages 302 - 307, XP002325957, ISSN: 1367-5931 *
POPKOV MIKHAIL ET AL: "Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: The impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display.", JOURNAL OF MOLECULAR BIOLOGY, vol. 325, no. 2, 10 January 2003 (2003-01-10), pages 325 - 335, XP002325954, ISSN: 0022-2836 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8674083B2 (en) 1999-01-15 2014-03-18 Genentech, Inc. Polypeptide variants with altered effector function
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US11993642B2 (en) 2009-04-07 2024-05-28 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US11999801B2 (en) 2014-12-03 2024-06-04 Hoffman-La Roche Inc. Multispecific antibodies
JP7227151B2 (en) 2017-03-22 2023-02-21 ジェネンテック， インコーポレイテッド Antibody Compositions Optimized for Treatment of Eye Disorders

Also Published As

Publication number Publication date
WO2005044853A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
WO2005044853A3 (en) Anti-vegf antibodies
WO2005012359A3 (en) Anti-vegf antibodies
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2007056470A3 (en) Neuropilin antagonists
WO2006133088A3 (en) Improved human interferon molecules and their uses
EP1812065A4 (en) High affinity antibodies against hmgb1 and methods of use thereof
EP1769245A4 (en) Identification and engineering of antibodies with variant fc regions and methods of using the same
WO2006053301A3 (en) Fc variants with altered binding to fcrn
WO2007076524A3 (en) Human anti-il-23 antibodies, compositions, methods and uses
IL178593A0 (en) Fc??riib-specific antibodies and methods of use thereof
WO2008143666A3 (en) Crystal structures of neuropilin fragments and neuropilin-antibody complexes
EP1587540A4 (en) IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2007097812A3 (en) Therapeutic anti-her2 antibody fusion polypeptides
IL189263A0 (en) Identification and engineering of antibodies with variant fc regions and methods of using same
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
EP1668114A4 (en) Polypeptide display libraries and methods of making and using thereof
WO2006112930A3 (en) Q3 sparc deletion mutant and uses thereof
EP2037737A4 (en) Proteins, nucleic acids encoding the same and associated methods of use
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
WO2005081873A9 (en) Il-13 mutein proteins, antibodies, compositions, methods and uses
WO2009097017A3 (en) Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
EA200801174A1 (en) GLP-2 MIMETIC ANTIBODIES, POLYPEPTIDES, COMPOSITIONS, METHODS AND APPLICATIONS
WO2008085987A3 (en) Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
IL183400A0 (en) New peptides useful as dual caspase-2/-6 inhibitors and their biological applications
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11414742

Country of ref document: US

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11414742

Country of ref document: US